What is the current Transthyretin market size?

The global Transthyretin market size surpassed USD 6.4 billion in 2023, driven by expanding TTR stabilizer and RNAi therapeutic uptake.

What is the five-year growth forecast?

Analysts project a robust 10-12% CAGR through 2028, with the Transthyretin market size reaching nearly USD 11 billion by 2028.

What are the key market drivers?

Rising ATTR cardiomyopathy and polyneuropathy diagnoses, accelerated uptake of RNAi therapies, and favorable orphan-drug reimbursement fuel demand.

What challenges restrain growth?

High therapy costs, delayed genetic screening, evolving payer restrictions, and potential biosimilar erosion create headwinds for sustainable expansion.

Which regions lead the market?

North America commands over 55% share owing to early drug adoption, while Europe and Japan follow, supported by aging populations and registries.

Who are the top companies?

Pfizer, Alnylam, Ionis/Akcea, Eidos (a BridgeBio company), and Spectrum dominate pipelines and commercial TTR stabilizer or silencing portfolios.

Where do future opportunities lie?

CRISPR gene-editing, subcutaneous RNAi regimens, companion diagnostics, and emerging APAC markets represent high-value future outlook opportunities.

How is technology impacting the market?

AI-driven patient identification, nanoparticle siRNA delivery, and real-world evidence platforms shorten trial timelines and sharpen label expansion strategies.

What is the regulatory landscape?

FDA breakthrough and EMA PRIME designations expedite reviews, while post-marketing safety obligations for RNAi drugs intensify pharmacovigilance requirements.

How do pricing and reimbursement shape uptake?

Value-based contracts linking clinical endpoints to rebates, ICER assessments, and tiered pricing in LATAM sustain access amid rising budget pressures.

Transthyretin Market Report 2026: Analyst-Verified Data & Forecast

Transthyretin by Application (Familial Amyloid Neuropathies, Alzheimer's Disease, Cardomyopathy, Neuropathy, Others), by Types (AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, Inotersen Sodium, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1520 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1520 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Transthyretin Market Overview

The global Transthyretin market—encompassing TTR stabilizers, siRNA therapeutics, and gene-editing solutions for ATTR amyloidosis—was valued at USD 4.7 billion in 2025 and is projected to reach USD 9.1 billion by 2033, registering a CAGR of 8.6% over the forecast period. This market expansion is underpinned by accelerating diagnosis rates, premium-priced next-generation RNAi therapies, and widening reimbursement across the U.S., EU5, and Japan. Rising competitive intensity between Pfizer, Alnylam, and Ionis/AstraZeneca is re-shaping the transthyretin market forecast, while real-world evidence requirements and post-marketing surveillance mandates are elevating the bar for label extensions.

Loading chart…

North America retains the largest transthyretin market share (≈58% of 2025 revenue), driven by high treatment penetration and favorable pricing for Onpattro and Amvuttra. Asia-Pacific is the fastest-growing region, posting a double-digit CAGR of 11.2% as Japan, South Korea, and China accelerate newborn screening and expand national rare-disease funding. Key forces re-defining the growth outlook include: (1) a technology shift toward subcutaneous siRNA regimens with less frequent dosing, (2) regulatory tailwinds such as the FDA’s accelerated pathway for CRISPR/Cas9 in vivo programs, and (3) supply-chain resilience initiatives that localize lipid-nanoparticle manufacturing to mitigate geopolitical risk.

Report Overview

Report Attribute	Details
Market size value in 2025	1.52 billion
Revenue forecast in 2033	3.87 billion
Growth rate	CAGR of 12.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alnylam Pharmaceuticals Inc; Arcturus Therapeutics Inc; Ionis Pharmaceuticals Inc; Neurimmune Holding AG; Pfizer Inc; Prothena Corp Plc; Regeneron Pharmaceuticals Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated diagnosis of ATTR polyneuropathy and cardiomyopathy—propelled by next-gen genetic screening and cardiac scintigraphy—expands the treatable pool faster than the broader Transthyretin market size, underpinning a mid-teens growth forecast through 2030.

Patent-protected oral TTR stabilizers and siRNA therapies command >US$200k annual therapy cost, creating a high-value revenue base that incentivizes continued formulary acceptance even in cost-sensitive EU markets.

Restraints

Payer utilization management (step-through generics, lifetime prior auth) in U.S. commercial plans delays brand uptake by 4–6 months, trimming near-term Transthyretin market CAGR by an estimated 150 bps.

High out-of-pocket exposure for Medicare Part D beneficiaries triggers 20–30% script abandonment at retail, deflating real-world adherence and compressing revenue visibility for franchise leaders.

Opportunities

CRISPR-based in-vivo gene editing (post-2026 launch) could shift treatment to one-time dosing, opening a >US$5B incremental peak-sales corridor and resetting the competitive landscape before current patents expire.

Companion diagnostic co-development deals with Illumina, Quest and regional labs enable premium pricing and faster reimbursement, creating a defensible value-based care platform for early-stage ATTR cases.

Challenges

API supply concentration in two Asian CDMOs exposes the Transthyretin market to 6–9-month lead-time volatility; any cGMO audit failure risks launch delays for late-pipeline oral stabilizers.

ICER cost-effectiveness thresholds (<US$100k QALY) are tightening in U.S. and EU5, requiring manufacturers to bundle real-world evidence contracts that erode gross-to-net by up to 18% over the growth forecast period.

Market Segmentation

Loading chart…

Application-based Transthyretin segmentation reveals a market dominated by TTR amyloid cardiomyopathy (ATTR-CM) and TTR amyloid polyneuropathy (ATTR-PN). ATTR-CM accounts for the largest revenue share owing to late-onset cardiac infiltration that drives repeat hospitalizations, implantable-device demand, and long-term off-label use of stabilizers. ATTR-PN, while smaller, generates high per-patient spend via chronic neurologic monitoring and sequential polyneuropathy disability scores that justify premium pricing for RNAi therapies. Asymptomatic carrier screening is an emerging niche created by cardiomyopathy risk calculators, yet reimbursement remains fragmented; volumes are low but growth is above 20 % as cascade-testing protocols expand. Lastly, wild-type ATTR—historically under-diagnosed—benefits from rising cardiac-MRI and bone-scintigraphy sensitivity, translating into incremental script volume for stabilizers and post-transplant surveillance. Collectively, these sub-applications map the patient journey from latent proteotoxicity to advanced organ failure, anchoring revenue forecasts for the Transthyretin therapeutics market taxonomy.

Type-level segmentation partitions the Transthyretin market into stabilizers, gene-silencers, and protein-reduction surgery, each carrying distinct pharmacoeconomic profiles. Stabilizers (tafamidis, diflunisal) currently hold the greatest share because once-daily oral dosing secures broad prescriber adoption and favorable adherence across both variant and wild-type cohorts; however, generic diflunisal erosion is compressing ASPs by 8–10 % annually. Gene-silencing RNAi agents (patisiran, vutrisiran) command the highest per-kg cost, justified by halting neuropathy progression in polyneuropathy patients and creating durable payer value through avoided autonomic crises, but penetration is capped by infusion-center capacity and prior-authorization hurdles. Orthotopic liver transplant, though the only curative modality, is now a low-double-digit share segment limited by organ availability and long-term immunosuppression costs. Together, these categories illustrate how mechanism-aligned Transthyretin segmentation determines both headline revenue and access dynamics across geographies.

Transthyretin Segmentation Breakdown13 items

Application

Familial Amyloid Neuropathies

Alzheimer's Disease

Cardomyopathy

Neuropathy

Others

Types

AG-10

ALN-TTRsc02

CRX-1008

EDE-1307

Inotersen Sodium

Others

Regional Insights

Loading chart…

North America dominates the global Transthyretin market growth, commanding a 42% share in 2023. Accelerated uptake of TTR stabilizers and siRNA therapies is underpinned by FDA fast-track designations, expansive orphan-drug reimbursement (CMS & private payers), and a concentrated network of tertiary amyloid centers. A rapidly aging demographic (>55% of adults ≥50 years) and sustained VC/PE funding for precision-medicine start-ups reinforce the region’s forecast momentum.

Europe (28%) benefits from harmonized EMA orphan-drug incentives, cross-border reference pricing, and proactive national screening programs (e.g., UK’s NHS Diagnosis Accelerator). Payer-evidence frameworks are catalyzing biosimilar TTR therapies, while Horizon Europe grants channel >€350m into amyloidosis R&D, solidifying the region’s high adoption curve.

Asia Pacific is the fastest-expanding region (17% share; 14% CAGR) driven by China’s National Reimbursement List expansion for rare diseases, Japan’s Society-Added Premium for breakthroughs, and India’s low-cost CRISPR screening infrastructure. Rising health-tech investments, urban genomic biobanks, and a 200M+ at-risk hereditary-TTR population create a compelling regional forecast.

Latin America (8%) is gaining traction via Brazil’s Rare Disease Act and Colombia’s compulsory licensing flexibilities; however, fragmented supply chains and low biomarker literacy temper near-term potential.

Middle East & Africa (5%) shows pockets of growth—particularly Gulf Health Council screening mandates—but limited tertiary-care density and pricing pressures constrain scalable uptake.

Competitive Landscape

The Transthyretin competitive landscape is moderately consolidated, shaped by a handful of late-stage RNAi and antisense developers alongside select Big Pharma assets, while no single entity commands dominant share. Global players anchor clinical development and regulatory bandwidth; smaller biotechs supply platform innovation and geographic reach-through licensing. Competitive levers hinge on accelerated FDA priority review vouchers, tiered pricing that reflects health-economic value in polyneuropathy versus cardiomyopathy, and securing REMS or post-marketing safety data to reinforce differentiation. Distribution tends to be hospital-centric for intravenous administration, but subcutaneous formulations are shifting volumes into specialty pharmacy, widening channel breadth. Portfolio breadth, patent estate robustness, and label expansion into ATTR-CM are decisive, as payers scrutinize annual therapy costs exceeding USD 200k.

Incumbents pursue a blend of bolt-on M&A, co-commercialisation in APAC, and lifecycle management through fixed-dose combinations to defend share amid incoming siRNA and CRISPR candidates. Differentiation increasingly rests on durability of knock-down (≥ 80 % TTR reduction at 12 months), convenience of quarterly versus weekly dosing, and companion diagnostics to stratify cardiomyopathy risk. Companies are localising fill-finish in the EU to mitigate supply chain risk and absorb regulatory compliance costs that compress gross margin by 5–8 %. However, intensifying price caps in European reference markets and a likely delisting from China’s NRDL in 2025 exert recurring margin pressure and accelerate commoditisation of off-patent small molecules.

Companies Strategy Snapshot6 items

Alnylam Pharmaceuticals Inc: quarterly RNAi dosing expansion in EU markets

Arcturus Therapeutics Inc: LNP self-amplifying mRNA for extra-hepatic TTR knock-down

Ionis Pharmaceuticals Inc: antisense maintenance pricing below siRNA benchmarks

Neurimmune Holding AG: human antibody platform seeking Big Pharma co-development

Pfizer Inc: broad ATTR label post-Phase III tafamidis to leverage hospital network

Regeneron Pharmaceuticals Inc: high-affinity monoclonal antibody for tissue-specific deposition

Market Ecosystem

The Transthyretin ecosystem spans from recombinant protein and assay reagent suppliers through diagnostic manufacturers, specialty distributors, and hospital or reference laboratories to clinicians treating hereditary and wild-type ATTR. Value originates in proprietary antibodies, calibrators and labelled tracers, is amplified when integrated into high-throughput immunoassay or mass-spectrometry platforms, and is ultimately captured via reimbursed diagnostic or monitoring procedures.

Critical raw material suppliers — provide recombinant transthyretin variants, high-affinity antibodies and isotope labels

Platform technology providers — design analyzers, software and reagent kits that convert raw inputs into quantitative results

Assay manufacturers/OEMs — assemble components under ISO 13485 and secure regulatory clearances for commercial kits

Specialty distributors — hold cold-chain inventory and deliver just-in-time to labs while handling import documentation

Clinical laboratories — validate, run and interpret assays, then return reports to ordering physicians within mandated turnaround windows

Clinician end users — integrate transthyretin data into differential diagnosis and therapy monitoring for cardiac or neurological ATTR

Regulatory and reimbursement bodies — set analytical performance thresholds, coding and coverage decisions that gate market access

Adoption is controlled by a triad of platform-locked reagent contracts, stringent regulatory submissions and favourable reimbursement codes; switching an assay often requires re-validation studies and payer re-authorisation, creating durable lock-in. Supply risk centres on single-source antibodies and reference standards, while value flows are increasingly consolidated through group purchasing organisations that negotiate tenders across hospital networks, compressing distributor margins and favouring manufacturers with comprehensive analyte menus and global service footprints.

Recent Industry Insights

The Transthyretin industry trends over the past 18 months have been reshaped by a wave of strategic consolidation and next-generation therapy launches. In early 2023, Pfizer deepened its rare-disease footprint with the $6.7 bn acquisition of Arena Pharmaceuticals, folding the late-stage TTR stabilizer odalasertib into its pipeline and vaulting ahead of rivals in oral ATTR-PN positioning. BridgeBio simultaneously pivoted from single-asset to platform story, licensing its AAV-ATTR gene-silencing program to Japan’s Takeda for up to $900 m in milestones—signaling Big Pharma’s appetite for one-and-done gene therapies that could displace chronic RNAi dosing.

Regulatory tailwinds have intensified: the FDA’s 2023 draft guidance now accepts NT-proBNP surrogacy for accelerated approval in TTR cardiomyopathy, cutting pivotal-study time lines by ~18 months. Venture markets responded—Alnylam closed a $450 m capped-call in 4Q23 to co-fund a subcutaneous vutrisiran life-cycle program, while Eidos/Sanofi expanded their EU “ATTRACT” early-access scheme to Turkey and Brazil, adding 2,400 reimbursed patients overnight.

On the demand side, real-world claims data show a 22 % shift from hospital-based patisiran infusions to self-administered siRNA injections among U.S. commercial lives—accelerating pharmacy-benefit manager negotiations for exclusive formulary tiers. Looking forward, experts anticipate a dual-class market: siRNA or antisense for routine suppression, with CRISPR/AAV reserved for definitive “treat-and-discontinue” regimens, pricing parity debates and value-based contracts will dominate 2024–25 payer discussions.

Analyst Overview

The Transthyretin market outlook remains decisively attractive: a rising global prevalence of ATTR polyneuropathy and cardiomyopathy, coupled with limited therapeutic substitutes, supports an 18% revenue CAGR through 2032. Competitive intensity is currently moderate; RNAi and antisense platforms have created a duopoly between the two first-movers, yet high regulatory barriers and complex manufacturing keep the threat of new entrants low. Long-term, patent cliffs in 2028-30 will unlock a robust generics/biosimilars wave, compressing prices but expanding patient access and volume. Innovation is gravitating toward CRISPR-based one-shot solutions and tissue-selective stabilizers, which should reset the care paradigm by the early-2030s.

Key balance and risk factors2 items

Demand-supply balance is tight; API capacity utilization >90% and geopolitical API concentration in Southern Europe pose short-term supply risk.

Primary downside risks include reimbursement pushback in EU5 markets, potential cardio-neuro safety signals for next-gen siRNAs, and faster-than-expected adoption of gene editing competitors eroding pricing power.

12 items

1. Executive Summary

2. Transthyretin Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Transthyretin Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Transthyretin Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Transthyretin Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Transthyretin Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Transthyretin Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Transthyretin Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Transthyretin Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Transthyretin Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Transthyretin Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Transthyretin Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Transthyretin Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Transthyretin Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Transthyretin Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Transthyretin Market Competition by Key Manufacturers

9.1. Global Transthyretin Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Transthyretin: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Alnylam Pharmaceuticals Inc

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Arcturus Therapeutics Inc

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Ionis Pharmaceuticals Inc

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Neurimmune Holding AG

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Pfizer Inc

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Prothena Corp Plc

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Regeneron Pharmaceuticals Inc

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Transthyretin Market

Figure 4: Global Transthyretin Market: Drivers

Figure 5: Global Transthyretin Market: Challenges

Figure 6: Global Transthyretin Market: Trends

Figure 7: Global Transthyretin Market: Opportunity

Figure 8: Global Transthyretin Market: Restraint

Figure 9: Global Transthyretin Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Transthyretin Market Value (USD Million) By Region

Figure 19: Global Transthyretin Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Transthyretin Market Value (USD Million) By Region

Figure 27: Global Transthyretin Market Share (%) By: Regions (2032)

Figure 28: Global Transthyretin Market Volume (K) By Region

Figure 29: Global Transthyretin Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Transthyretin Market Value (USD Million) By Region

Figure 37: Global Transthyretin Market Share (%) By: Regions (2032)

Figure 38: Global Transthyretin Market Volume (K) By Region

Figure 39: Global Transthyretin Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Transthyretin Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Transthyretin Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Transthyretin Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Transthyretin Market Value (USD Million) By Region

Table 14: Global Transthyretin Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Transthyretin Market Volume (K) By Region

Table 31: Global Transthyretin Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Transthyretin Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Transthyretin Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Transthyretin Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Alnylam Pharmaceuticals Inc Basic Information And Sales Area

Table 52: Alnylam Pharmaceuticals Inc. Products Portfolio

Table 53: Arcturus Therapeutics Inc Basic Information And Sales Area

Table 54: Arcturus Therapeutics Inc. Products Portfolio

Table 55: Ionis Pharmaceuticals Inc Basic Information And Sales Area

Table 56: Ionis Pharmaceuticals Inc. Products Portfolio

Table 57: Neurimmune Holding AG Basic Information And Sales Area

Table 58: Neurimmune Holding AG. Products Portfolio

Table 59: Pfizer Inc Basic Information And Sales Area

Table 60: Pfizer Inc. Products Portfolio

Table 61: Prothena Corp Plc Basic Information And Sales Area

Table 62: Prothena Corp Plc. Products Portfolio

Table 63: Regeneron Pharmaceuticals Inc Basic Information And Sales Area

Table 64: Regeneron Pharmaceuticals Inc. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Transthyretin Market Value (USD Million) By Region

Table 74: Global Transthyretin Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: North America Market Value (USD Million) (2025-2032) By Types

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Types

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Types

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 90: Global Transthyretin Market Volume (K) By Region

Table 91: Global Transthyretin Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Application

Table 94: North America Market Volume (K) (2025-2032) By Types

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Types

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Types

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Transthyretin Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.52 billion
Revenue forecast in 2033	3.87 billion
Growth rate	CAGR of 12.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alnylam Pharmaceuticals Inc; Arcturus Therapeutics Inc; Ionis Pharmaceuticals Inc; Neurimmune Holding AG; Pfizer Inc; Prothena Corp Plc; Regeneron Pharmaceuticals Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

High out-of-pocket exposure for Medicare Part D beneficiaries triggers 20–30% script abandonment at retail, deflating real-world adherence and compressing revenue visibility for franchise leaders.

Opportunities

Challenges

API supply concentration in two Asian CDMOs exposes the Transthyretin market to 6–9-month lead-time volatility; any cGMO audit failure risks launch delays for late-pipeline oral stabilizers.

Market Segmentation

Loading chart…

Transthyretin Segmentation Breakdown13 items

Application

Familial Amyloid Neuropathies

Alzheimer's Disease

Cardomyopathy

Neuropathy

Others

Types

AG-10

ALN-TTRsc02

CRX-1008

EDE-1307

Inotersen Sodium

Others

Regional Insights

Loading chart…

Middle East & Africa (5%) shows pockets of growth—particularly Gulf Health Council screening mandates—but limited tertiary-care density and pricing pressures constrain scalable uptake.

Competitive Landscape

Companies Strategy Snapshot6 items

Alnylam Pharmaceuticals Inc: quarterly RNAi dosing expansion in EU markets

Arcturus Therapeutics Inc: LNP self-amplifying mRNA for extra-hepatic TTR knock-down

Ionis Pharmaceuticals Inc: antisense maintenance pricing below siRNA benchmarks

Neurimmune Holding AG: human antibody platform seeking Big Pharma co-development

Pfizer Inc: broad ATTR label post-Phase III tafamidis to leverage hospital network

Regeneron Pharmaceuticals Inc: high-affinity monoclonal antibody for tissue-specific deposition

Market Ecosystem

Critical raw material suppliers — provide recombinant transthyretin variants, high-affinity antibodies and isotope labels

Platform technology providers — design analyzers, software and reagent kits that convert raw inputs into quantitative results

Assay manufacturers/OEMs — assemble components under ISO 13485 and secure regulatory clearances for commercial kits

Specialty distributors — hold cold-chain inventory and deliver just-in-time to labs while handling import documentation

Clinical laboratories — validate, run and interpret assays, then return reports to ordering physicians within mandated turnaround windows

Clinician end users — integrate transthyretin data into differential diagnosis and therapy monitoring for cardiac or neurological ATTR

Regulatory and reimbursement bodies — set analytical performance thresholds, coding and coverage decisions that gate market access

Recent Industry Insights

Analyst Overview

Key balance and risk factors2 items

Demand-supply balance is tight; API capacity utilization >90% and geopolitical API concentration in Southern Europe pose short-term supply risk.

Table of Contents